In PARP inhibitor-sensitive HGSOC cancers, the significantly lower expression of four genes (tyrosine-protein kinase Met or hepatocyte growth factor receptor-C-MET, cyclin-dependent kinase inhibitor 2A-CDKN2A, N-cadherin, and P-glycoprotein/ATP binding cassette subfamily B member 1-P-glyc/ABCB1) was noted. This evidence concerns the gene CDKN2A and cancer.